Moderna Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Moderna with us today. And with us is Stéphane Bancel, CEO of the company.
Questions & Answers
So Stéphane, to start here, just given the COVID-19 pandemic, Moderna has the opportunity here to demonstrate the potential of the mRNA platform as it relates to vaccine development over the course of a few months versus what would have typically taken 2 to 5 years or maybe even more. Why is Moderna positioned to successfully develop a vaccine and supply it to the global population?
© -
Yes. So Salveen, good afternoon, and thank you for having us. I think a few reasons. I mean first, we believed since we started the company, that mRNA could be potentially the best
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |